Analysis of therapeutic effects on type II respiratory failure and impact on blood gas changes: high-flow nasal oxygen therapy vs. non-invasive positive pressure ventilation.

Yongping Liu, Ning Liu, Ying Li, Lixiu Nie, Lin Li

Abstract read

In one paragraph

Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yongping LiuDepartment of Internal Medicine, Xi'an International Medical Center Hospital No. 777 Xitai Road, Chang'an District, Xi'an 710000, Shaanxi, China.

Ning LiuDepartment of Cardiovascular Medicine, Urumqi Friendship Hospital No. 558 Shengli Road, Tianshan District, Urumqi 830049, The Xinjiang Uygur Autonomous Region, China.

Ying LiDepartment of General Medicine, Xi'an International Medical Center Hospital No. 777 Xitai Road, Chang'an District, Xi'an 710000, Shaanxi, China.

Lixiu NieDepartment of Respiratory and Critical Care Medicine, The Second People's Hospital of Lanzhou City No. 388 Jingyuan Road, Chengguan District, Lanzhou 730046, Gansu, China.

Lin LiDepartment of Respiratory and Critical Care Medicine, The Second People's Hospital of Lanzhou City No. 388 Jingyuan Road, Chengguan District, Lanzhou 730046, Gansu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the efficacy of high-flow nasal oxygen therapy (HFNO) vs. non-invasive positive pressure ventilation (NIPPV) in type II respiratory failure, and analyze their impact on blood gas parameters.

methodsA retrospective analysis of 110 cases of type II respiratory failure treated from April 2021 to March 2023 categorized patients into control (NIPPV, n=50) and observation (HFNO, n=60) groups. Both groups received comprehensive nursing interventions. Treatment outcomes, respiratory and hemodynamic parameters, blood gas parameters, and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores were compared before and 48 hours after treatment. Additionally, the complication rates and independent risk factors affecting prognosis were analyzed.

resultsThe observation group exhibited superior treatment efficacy compared to the control group (P=0.001). Both groups showed significant improvements in APACHE II scores and respiratory, hemodynamic, and blood gas parameters after treatment (P<0.001), with the observation group experiencing more pronounced improvements (P<0.001). The observation group also had a lower incidence of complications than the control group (P=0.013). Logistic regression identified PaCO

conclusionHFNO demonstrates superior therapeutic efficacy in type II respiratory failure, significantly improving blood gas parameters with a high level of safety, supporting its clinical applicability.

Indexed as

blood gas parametersHigh-flow nasal oxygen therapynon-invasive positive pressure ventilationtherapeutic effectstype II respiratory failure

Identifiers

PMID38463604

PMCPMC10918141

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.